Summit Therapeutics Inc.

NASDAQ•SMMT

CEO: Mr. Robert W. Duggan

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2015-03-05

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Contact Information

601 Brickell Key Drive, Suite 1000, Miami, FL, 33131, United States

650-460-8308

www.summittxinc.com

Market Cap

$11.61B

P/E (TTM)

-10.8

17.3

Dividend Yield

52W High

$36.91

52W Low

$13.83

52W Range

Rank55Top 80.0%

2.6

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.29+0.00%

4-Quarter Trend

FCF

-$100.16M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

BLA Accepted for Ivonescimab Filing FDA accepted BLA for ivonescimab plus chemo in Q4 2025; PDUFA goal action date set for November 14, 2026.

Significant R&D Investment Increase R&D expenses reached $537.7 M in 2025, up $386.9 M, driven by new clinical trials and stock compensation.

HARMONi PFS Benefit Demonstrated HARMONi trial showed median PFS 6.8 months (ivonescimab) versus 4.4 months (placebo); HR 0.52.

Raised $617.5 Million Capital Total financing proceeds $617.5 M provided in 2025, including $500.0 M private placement, funding operations.

Risk Factors

Continued Substantial Operating Losses Incurred $1.08 B net loss in 2025; expects significant losses for several future years requiring capital raises.

Ivonescimab Regulatory Uncertainty FDA noted OS benefit necessary for approval; primary HARMONi OS analysis lacked statistical significance.

High Stock-Based Compensation G&A expenses surged due to $513.8 M stock-based compensation following option award modification in Q2 2025.

Related Party Litigation Exposure Derivative lawsuit filed March 2025 concerning December 2022 Notes; defendants plan vigorous defense against claims.

Outlook

Execute BLA Review Process Focus on FDA review process for ivonescimab BLA, including planned mid-cycle and wrap-up meetings through 2026.

Expand Phase III Clinical Trials Continue enrolling patients in HARMONi-3 (NSCLC) and HARMONi-GI3 (CRC) trials across multiple regions.

Build Commercialization Infrastructure Actively hiring commercial leadership and building infrastructure to support potential future launch of ivonescimab.

Seek Additional Future Financing Expect to require additional equity or debt financing to fund ongoing operations and potential milestone payments to Akeso.

Peer Comparison

Revenue (TTM)

CNC

$194.78B

+19.4%

THC

$21.31B

+3.1%

UHS

$17.36B

+9.7%

Gross Margin (Latest Quarter)

RNA

100.0%

+0.0pp

RPRX

100.0%

+0.0pp

IONS

96.1%

-0.7pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
UTHR	$22.84B	17.3	19.3%	0.0%
MRNA	$20.25B	-7.1	-30.1%	15.5%
EXAS	$20.03B	-95.7	-8.5%	43.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 29, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data